Casopitant

Star0

DB06634InvestigationalSmall molecule

Investigated for use/treatment in urinary incontinence and adverse effects (chemotherapy).

Mechanism: Pharmacologically active on Substance-P receptor
Curator reviewed
Primary indication: Investigated for use/treatment in urinary incontinence and adverse effects (chemotherapy).Curator reviewed
Formula / weight: C₃₀H₃₅F₇N₄O₂ · 616.625 g/mol (avg)
Code names: 679769 · GW-679769

Resolves to

Compound

UNII3B03KPM27LCAS414910-27-3ChEMBLCHEMBL1672054ChEBI135967

Clinical / RWD

ATCA04AD13PharmGKBPA166129533

Structure

InChIKeyXGGTZCKQRWXCHW-WMTVXVAQSA-NSMILESC[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN(CC1)C(C)=O)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F

Targets

P25103TACR1P08684CYP3A4

What you can answer from here — as of September 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

20Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 10 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Casopitant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account